Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Published:2015-08-27 Issue:2 Volume:24 Page:911-925
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Gascón Pere,Aapro Matti,Ludwig Heinz,Bokemeyer Carsten,Boccadoro Mario,Turner Matthew,Denhaerynck Kris,MacDonald Karen,Abraham Ivo

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-015-2861-z.pdf

Reference34 articles.

1. Lalami Y, Paesmans M, Muanza F et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17:507–514

2. Lalami Y, Paesmans M, Aoun M et al (2004) A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 12:725–730

3. Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437

4. Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475–2484

5. Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190–199

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04

2. Clinical decision support for chemotherapy‐induced neutropenia using a hybrid pharmacodynamic/machine learning model;CPT: Pharmacometrics & Systems Pharmacology;2023-08-10

3. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study;Journal of Medical Economics;2023-03-14

4. G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study;Cancer Treatment and Research Communications;2023

5. Safety profile of G-CSF in chemotherapy-induced neutropenia;Indian Journal of Cancer;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3